Trial Profile

A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabotamig (Primary) ; Atezolizumab
Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Intestinal cancer; Liver cancer; Pancreatic cancer
Focus Adverse reactions; First in man
Sponsors Arbele

Most Recent Events

19 Mar 2026 Actual Primary Completion date changed to 23 Jul 2025
19 Mar 2026 Status changed from recruiting to completed.
04 Sep 2025 Planned End Date changed from 1 Aug 2025 to 1 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com